ArticleBritish journal of cancer2014

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.

C Papadaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.